keyword
https://read.qxmd.com/read/38498036/a-lineage-specific-stat5bn642h-mouse-model-to-study-nk-cell-leukemia
#1
JOURNAL ARTICLE
Klara Klein, Sebastian Kollmann, Angela Hiesinger, Julia List, Jonatan Kendler, Thorsten Klampfl, Mehak Randhawa, Jana Trifinopoulos, Barbara Maurer, Reinhard Grausenburger, Christof A Bertram, Richard H Moriggl, Thomas Rülicke, Charles G Mullighan, Agnieszka Witalisz-Siepracka, Wencke Walter, Gregor Hoermann, Veronika Sexl, Dagmar Gotthardt
Patients with T- and NK-cell neoplasms frequently have somatic STAT5B gain-of-function mutations. The most frequent STAT5B mutation is STAT5BN642H, which is known to drive murine T-cell leukemia although its role in NK-cell malignancies is unclear. Introduction of the STAT5BN642H mutation into human NK-cell lines enhances their potential to induce leukemia in mice. We have generated a mouse model that enables tissue-specific expression of STAT5BN642H and have selectively expressed the mutated STAT5B in hematopoietic cells (N642Hvav/+) or exclusively in NK cells (N642HNK/NK)...
March 18, 2024: Blood
https://read.qxmd.com/read/38493239/beyond-the-marrow-insights-from-comprehensive-next-generation-sequencing-of-extramedullary-multiple-myeloma-tumors
#2
JOURNAL ARTICLE
T Jelinek, D Zihala, T Sevcikova, A Anilkumar Sithara, V Kapustova, H Sahinbegovic, O Venglar, L Muronova, L Broskevicova, S Nenarokov, D Bilek, T Popkova, H Plonkova, J Vrana, V Zidlik, P Hurnik, M Havel, M Hrdinka, Z Chyra, G Stracquadanio, M Simicek, R Hajek
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors (N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2...
March 16, 2024: Leukemia
https://read.qxmd.com/read/38464517/key-candidate-genes-and-pathways-in-t-lymphoblastic-leukemia-lymphoma-identified-by-bioinformatics-and-serological-analyses
#3
JOURNAL ARTICLE
Yansong Ren, Haoyue Liang, Yali Huang, Yuyang Miao, Ruihua Li, Junlian Qiang, Lihong Wu, Jinfeng Qi, Ying Li, Yonghui Xia, Lunhui Huang, Shoulei Wang, Xiaodong Kong, Yuan Zhou, Qiang Zhang, Guoqing Zhu
T-cell acute lymphoblastic leukemia (T - ALL)/T-cell lymphoblastic lymphoma (T-LBL) is an uncommon but highly aggressive hematological malignancy. It has high recurrence and mortality rates and is challenging to treat. This study conducted bioinformatics analyses, compared genetic expression profiles of healthy controls with patients having T-ALL/T-LBL, and verified the results through serological indicators. Data were acquired from the GSE48558 dataset from Gene Expression Omnibus (GEO). T-ALL patients and normal T cells-related differentially expressed genes (DEGs) were investigated using the online analysis tool GEO2R in GEO, identifying 78 upregulated and 130 downregulated genes...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38436833/comprehensive-insight-into-the-functional-roles-of-nk-and-nkt-cells-in-htlv-1-associated-diseases-and-asymptomatic-carriers
#4
REVIEW
Maryam Mahdifar, Reza Boostani, Graham P Taylor, Seyed Abdolrahim Rezaee, Houshang Rafatpanah
Human T cell leukemia virus type 1 (HTLV-1) is the first human oncogenic retrovirus to be discovered and causes two major diseases: a progressive neuro-inflammatory disease, termed HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), and an aggressive malignancy of T lymphocytes known as adult T cell leukemia (ATL). Innate and acquired immune responses play pivotal roles in controlling the status of HTLV-1-infected cells and such, the outcome of HTLV-1 infection. Natural killer cells (NKCs) are the effector cells of the innate immune system and are involved in controlling viral infections and several types of cancers...
March 4, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38330588/aggressive-nk-cell-leukemia-a-case-report-and-literature-review
#5
JOURNAL ARTICLE
Zhao Chen, Can Liu, Jianjun Chen, Ping Lei, Shan Feng, Guanghua Liu, Daiyou Dai, Jun Cao, Jiangchuan Chen, Jianfeng Zhou, Ming Zhou
OBJECTIVE: To improve the understanding of aggressive NK-cell leukemia (ANKL) and summarize the progress of its diagnosis and treatment. METHODS: We retrospectively analyzed a case of a patient who was initially diagnosed with T-cell lymphoma (non-specific type) and later transformed into ANKL through examinations such as bone marrow smear, flow cytometry, Q-mNGS, and pathology. We described the patient's diagnostic and treatment journey and conducted a literature review...
January 31, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38319083/clinical-features-and-prognosis-of-chronic-natural-killer-cell-lymphoproliferative-disorders
#6
JOURNAL ARTICLE
Dong-Lin Liu, Yan-Jie Wang, Si-Yu Qian, Shan-Shan Ma, Meng-Jie Ding, Meng Dong, Jie-Ming Zhang, Ming-Zhi Zhang, Qing-Jiang Chen, Xu-Dong Zhang
OBJECTIVE: To analyze the current treatment status and prognostic regression of the chronic NK cell lymphoproliferative disorder (CLPD-NK). METHODS: We retrospectively analyzed the clinical features, treatment and prognosis of 18 patients with CLPD-NK who were treated at our Hospital between September 2016 and September 2022. RESULTS: Eighteen patients were included: three patients were treated with chemotherapy, five patients underwent immune-related therapy, one patient was treated with glucocorticoids alone, five patients were administered granulocyte colony-stimulating factor, blood transfusion therapy, or anti-infection therapy, followed by observation and follow-up, and four patients were observed without treatment...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38173114/-atypical-lymphocytosis-report-of-two-cases-and-literature-review
#7
JOURNAL ARTICLE
Ya-Xin Shan, Jing Li, Xiang Yang, Lin Li, Zou-Fang Huang
To improve the diagnosis of atypical lymphocytes and reduce the misdiagnosis rate,we analyzed the medical records of 2 cases with cell morphology suggestive of atypical lymphocytes.One case was diagnosed with infectious mononucleosis and the other with aggressive NK cell leukemia.The purpose of this paper is to emphasize that the diagnosis of atypical lymphocytes based only on morphological interpretation of cells may be incorrect,which should be combined with clinical symptoms,signs,imaging examination,cell immunophenotype,and disease outcome...
December 30, 2023: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://read.qxmd.com/read/38132278/blastic-plasmocytoid-dendritic-cell-neoplasm-bpdcn-clinical-features-and-histopathology-with-a-therapeutic-overview
#8
REVIEW
Gerardo Cazzato, Marialessandra Capuzzolo, Emilio Bellitti, Giovanni De Biasi, Anna Colagrande, Katia Mangialardi, Francesco Gaudio, Giuseppe Ingravallo
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites. The rarity and relative poor description of cases in the literature make it necessary to review and further studies that deeply investigate this entity not only in a histopathological but also molecular field. In August-September 2023, we searched MEDLINE, PubMed and Scopus for randomized controlled trials (RCTs), narrative and systematic reviews, meta-analyses, observational studies (either longitudinal or retrospective), and case series published in English in the last 25 years using the keywords BPDCN, PDCs, Blastic NK-cell lymphoma, agranular CD4+ NK leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm/tumor...
December 8, 2023: Hematology Reports
https://read.qxmd.com/read/38129572/hyperactive-natural-killer-cells-in-rag2-knockout-mice-inhibit-the-development-of-acute-myeloid-leukemia
#9
JOURNAL ARTICLE
Emi Sugimoto, Jingmei Li, Yasutaka Hayashi, Kohei Iida, Shuhei Asada, Tsuyoshi Fukushima, Moe Tamura, Shiori Shikata, Wenyu Zhang, Keita Yamamoto, Kimihito Cojin Kawabata, Tatsuya Kawase, Takeshi Saito, Taku Yoshida, Satoshi Yamazaki, Yuta Kaito, Yoichi Imai, Tamami Denda, Yasunori Ota, Tomofusa Fukuyama, Yosuke Tanaka, Yutaka Enomoto, Toshio Kitamura, Susumu Goyama
Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers including acute myeloid leukemia (AML). In this study, we found that the development of several aggressive subtypes of AML is slower in Rag2-/- mice despite the lack of B and T lymphocytes, even compared to the immunologically normal C57BL/6 mice. Furthermore, an orally active p53-activating drug shows stronger antileukemia effect on AML in Rag2-/- mice than C57BL/6 mice. Intriguingly, Natural Killer (NK) cells in Rag2-/- mice are increased in number, highly express activation markers, and show increased cytotoxicity to leukemia cells in a coculture assay...
December 21, 2023: Communications Biology
https://read.qxmd.com/read/38104292/an-unexpected-presentation-of-a-maxillary-non-hodgkin-lymphoma-in-an-elderly-hispanic-patient
#10
JOURNAL ARTICLE
Dalianie Nieves, Elias Sobrino, William Caceres-Perkins, Trevor L Kuttler, Fernando Cabanillas
Extranodal NK/T-cell lymphoma (ENKTL), nasal type and aggressive NK cell leukemia are rare in Western World been less than 1% in USA to 8% in Asia among Non-Hodgkin's lymphomas. It is aggressive, with poor outcome and optimal treatment is unclear. A combination therapy that includes Peg-Asparaginase (SMILE) has been employed in young patients. An 85-year-old Puerto Rican male presented with anorexia, epistaxis, vertigo and involuntary facial movements. He was treated with injectable Onabotulinum toxin A due to suspicion of a hemifacial spasm...
December 2023: Puerto Rico Health Sciences Journal
https://read.qxmd.com/read/38016421/cytogenetics-in-the-management-of-mature-t-cell-and-nk-cell-neoplasms-guidelines-from-the-groupe-francophone-de-cytog%C3%A3-n%C3%A3-tique-h%C3%A3-matologique-gfch
#11
Jean-Baptiste Gaillard, Elise Chapiro, Agnès Daudignon, Nathalie Nadal, Dominique Penther, Jasmine Chauzeix, Florence Nguyen-Khac, Lauren Veronese, Christine Lefebvre
Mature T-cell and natural killer (NK)-cell neoplasms (MTNKNs) are a highly heterogeneous group of lymphomas that represent 10-15 % of lymphoid neoplasms and have usually an aggressive behavior. Diagnosis can be challenging due to their overlapping clinical, histological and immunophenotypic features. Genetic data are not a routine component of the diagnostic algorithm for most MTNKNs. Indeed, unlike B-cell lymphomas, the genomic landscape of MTNKNs is not fully understood. Only few characteristic rearrangements can be easily identified with conventional cytogenetic methods and are an integral part of the diagnostic criteria, for instance the t(14;14)/inv(14) or t(X;14) abnormality harbored by 95 % of patients with T-cell prolymphocytic leukemia, or the ALK gene translocation observed in some forms of anaplastic large cell lymphoma...
October 31, 2023: Current Research in Translational Medicine
https://read.qxmd.com/read/37803436/possible-concomitant-aggressive-nk-cell-leukemia-and-ebv-positive-t-cell-lymphoma-using-the-online-beta-version-of-who-haem5-and-videoconferencing-software-to-make-diagnoses-accessible-in-an-emerging-economy
#12
JOURNAL ARTICLE
Vanessa J Dayton, Dang Hoang Thien, Phan Thi Xinh, Cade Arries, Nguyen Ngoc Sang, Ngo Ngoc Ngan Linh, Nguyen Phuong Lien, Phu Chi Dung
BACKGROUND: Using the World Health Organization Classification 5th edition (beta version online; WHO-HAEM5bv) in emerging economies is key to global healthcare equity. Although there may be ongoing updates, hesitancy in accepting and reporting these diagnoses in publication conflicts with the WHO's commitment to global accessibility. Aggressive NK cell leukemia (ANKL) and systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL) with CD4-positive immunophenotype are both rare entities, are most described in Asians and East Asians, are associated with prior systemic chronic active EBV disease (CAEBV), and presentation with Hemophagocytic Lymphohistiocytosis (HLH)...
October 6, 2023: Diagnostic Pathology
https://read.qxmd.com/read/37794819/use-of-pd-1-blockade-in-refractory-relapsed-natural-killer-t-cell-lymphomas-a-systematic-review-and-synthesis-of-case-reports
#13
JOURNAL ARTICLE
Victor M Rivera-Francia, Virgilio E Failoc-Rojas, Robert Villacorta-Carranza, Alejandro Leon Garrido-Lecca, Ana Calle-Villavicencio, Alicia Torres-Mera, Mario J Valladares-Garido, Yesenia Huerta-Collado, Rodrigo Motta-Guerrero, Luis Casanova Marquez
Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin's lymphoma with limited treatment options for patients who experience disease progression or recurrence after second-line treatment. The use of new therapies, such as pembrolizumab, which involves immune checkpoint blockade mechanisms, is proposed. This systematic review followed the MOSE guidelines and searched PUBMED/MEDLINE, EMBASE, and Scopus databases. Fourteen articles were found, reporting on the use of pembrolizumab anti PD-1 in NK/T-cellL patients...
October 5, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37691822/molecular-subtyping-of-acute-myeloid-leukemia-through-ferroptosis-signatures-predicts-prognosis-and-deciphers-the-immune-microenvironment
#14
JOURNAL ARTICLE
Denggang Fu, Biyu Zhang, Shiyong Wu, Jueping Feng, Hua Jiang
Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. Developing more efficient therapies is an urgent need for AML treatment. Accumulating evidence showed that ferroptosis, an iron-dependent form of programmed cell death, is closely correlated with cancer initiation and clinical outcome through reshaping the tumor microenvironment. However, understanding of AML heterogeneity based on extensive profiling of ferroptosis signatures remains to be investigated yet...
2023: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/37661142/extensive-hemophagocytic-lymphohistiocytosis-associated-with-aggressive-natural-killer-cell-leukemia
#15
JOURNAL ARTICLE
Xi Zhang, Min Shi
No abstract text is available yet for this article.
September 2023: Mayo Clinic Proceedings
https://read.qxmd.com/read/37638009/case-report-molecular-and-microenvironment-change-upon-midostaurin-treatment-in-mast-cell-leukemia-at-single-cell-level
#16
Meng-Ke Liu, Feng Liu, Yu-Ting Dai, Xiang-Qin Weng, Li-Li Cheng, Li-Quan Fan, Han Liu, Lu Jiang, Xiao-Jian Sun, Hai Fang, Li Wang, Wei-Li Zhao
Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefore, the potential mechanisms of midostaurin resistance and the exact impacts of midostaurin on both gene expression profile and mast cell leukemia microenvironment in vivo are essential for design tailored combination therapy targeting both the tumor cells and the tumor microenvironment...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37584500/limocitrin-increases-cytotoxicity-of-khyg-1-cells-against-k562-cells-by-modulating-mapk-pathway
#17
JOURNAL ARTICLE
Ming-Ju Hsieh, Jen-Tsun Lin, Yi-Ching Chuang, Chia-Chieh Lin, Yu-Sheng Lo, Hsin-Yu Ho, Mu-Kuan Chen
Natural killer (NK) cells are gaining popularity in the field of cancer immunotherapy. The present study was designed to investigate the effect of a natural flavonol compound limocitrin in increasing cytotoxicity of a permanent NK leukemia cell line KHYG-1 against an aggressive leukemia cell line K562. The findings revealed that limocitrin increased the expressions of cytolytic molecules perforin, granzymes A and B, and granulysin in KHYG-1 cells by inducing phosphorylation of transcription factor CREB, leading to increased lysis of K562 cells...
August 16, 2023: Environmental Toxicology
https://read.qxmd.com/read/37551472/-clinical-characteristics-of-aggressive-nk-cell-leukemia
#18
JOURNAL ARTICLE
Yi Liao, He-Sheng He, Yuan-Feng Wei, Da-Peng Shen, Xin-Yue Ji, Chen Huang, Jun Huang, Xiao-Ke Jin, Dong-Ping Huang
OBJECTIVE: To explore and summarize the clinical characteristics and treatment of aggressive NK-cell leukemia (ANKL), and provide new insights for clinical diagnosis and treatment of this disease. METHODS: The clinical data of 7 patients with ANKL admitted to the First Affiliated Hospital of Wannan Medical College from March 2014 to July 2021 were retrospectively analyzed, and their clinical characteristics, laboratory and imaging results, treatment and outcomes were analyzed...
August 2023: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/37464744/acute-and-persistent-remission-of-aggressive-natural-killer-cell-leukemia-in-an-older-patient-induced-by-chidamide-combined-with-cyclophosphamide-vindesine-prednisone-and-etoposide-therapy
#19
JOURNAL ARTICLE
Qingqing Lin, Renzhi Pei, Ying Lu
No abstract text is available yet for this article.
July 19, 2023: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://read.qxmd.com/read/37444389/b7-h3-in-pediatric-tumors-far-beyond-neuroblastoma
#20
REVIEW
Cristina Bottino, Chiara Vitale, Alessandra Dondero, Roberta Castriconi
B7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints. Besides neuroblastoma, B7-H3 is expressed by many pediatric cancers including tumors of the central nervous system, sarcomas, and acute myeloid leukemia. In children, particularly those affected by solid tumors, the therapeutic protocols are aggressive and cause important life-threatening side effects...
June 21, 2023: Cancers
keyword
keyword
69611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.